Dimethyl fumarate

Biogen cut its annual guidance as it said that the cost of two recent deals will weigh on profit in the final quarter of the year, dragging it down by $1.25 per share. The company indicated that earnings per share in 2025 are now predicted to be between $14.50 and $15.00, trimmed from an earlier range of $15.50 to $16.00. In September, Biogen agreed to acquire Alcyone Therapeutics, gaining full rights to the latter’s investigational intrathecal drug delivery system for an upfront cash payment of $85 million. More recently, Biogen licensed a preclinical oral C5aR1 antagonist from Vanqua Bio for $70 million upfront. The company said that it expects to incur charges of around $225 million in the fourth quarter related to the Alcyone and Vanqua transactions, as well as an additional one or two research-stage deals that will be announced by the end of the year. Resilience in MS Having previously guided for flat sales in 2025, Biogen said that revenue may now grow by up to 1% on a constant currency basis. The company explained that despite increased competition to Tecfidera in Europe in the fourth quarter, the uplift reflects the resilience of its multiple sclerosis (MS) business in the US. In the third quarter, sales of MS products increased 1% to $1.1 billion, while revenue from Friedreich's ataxia therapy Skyclarys climbed 30% to $133 million. Biogen's overall sales climbed 3% to $2.5 billion, with net income reaching $466.5 million, up from $388.5 in the prior-year period. "We delivered another quarter of strong financial performance driven by continued commercial momentum in our launch products, resilience in our MS franchise and our ongoing focus on disciplined cost management," remarked CEO Christopher Viehbacher.  Biogen said that Eisai-partnered Alzheimer's disease drug Leqembi achieved global sales of $121 million in the third quarter, representing year-over-year growth of 82%. Revenue from the product in the US reached $69 million, showing "continued steady growth."

Generic dimethyl fumarate delayed-release capsules are 2nd launch in 3 months Average savings of $4,300/month compared with other generic versions LEHI, Utah, June 24, 2025 /PRNewswire/ -- CivicaScript®, LLC, a nonprofit company dedicated to bringing low-cost generic medicines to U.S. patients, today announced the availability of dimethyl fumarate delayed-release capsules. Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults, to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. CivicaScript will offer dimethyl fumarate 240 mg capsules for sale to pharmacies for $47 per bottle of 60 capsules – typically a month's supply. CivicaScript recommends that pharmacies charge patients no more than $68 per bottle (CivicaScript's maximum retail price, or MaxRP TM). CivicaScript's MaxRP policy provides a way for healthcare providers, caregivers, patients and others to compare prices; consumers can confirm they are being charged no more than the MaxRP by scanning the QR code featured on the CivicaScript product label. CivicaScript will offer the 120 mg and 240 mg strengths of dimethyl fumarate capsules for sale. CivicaScript's MaxRP for dimethyl fumarate is about $4,300 per month less than the average claim cost for prescriptions filled at traditional PBM-affiliated pharmacies. 1 It could significantly reduce patients' out-of-pocket costs during the deductible phase of their health insurance, in which they pay full price for their medicines. Savings also could be substantial for patients with co-insurance, which charges them a percentage of their medicines' price. "Today's launch is yet another step in our journey to make necessary medications more affordable for the patients who need them," said CivicaScript President Brent J. Eberle. "We're bringing transparency and affordability to the generic drug market in a sustainable way – saving money for patients and payers and making medicines more accessible." The launch comes on the heels of a report in The New England Journal of Medicine Catalyst that CivicaScript's abiraterone saved consumers 64% and payers 92% when they switched from other versions of the same drug. CivicaScript partners with manufacturers to produce low-cost generic medicines, then works with payers and pharmacies across the country to pass along the cost savings to patients. CivicaScript's business model focuses on transparency and collaboration throughout the value chain from manufacturing through dispensing — with every stakeholder along the way knowing the price of the medicine and driving savings through to the patient. Dimethyl fumarate was chosen by CivicaScript members as a priority generic medicine based on its high list price from other manufacturers and significant patient need for the product. While many generic medicines cost less than brand-name drugs, some high-cost generics are more expensive than they need to be. Numerous studies confirm that medication costs can dictate whether patients ration their prescriptions or even fill them in the first place. About CivicaScript CivicaScript is bringing unprecedented transparency to the drug supply chain to make quality generic medicines affordable and available for everyone. A nonprofit company, CivicaScript is committed to the principles of providing affordable, essential generic medicines to promote the social welfare and health of the community. For more information on the organization and our mission, visit our website. CivicaScript is the Civica, Inc. operating unit for outpatient medications to help drive affordability and price transparency. About dimethyl fumarate For full prescribing information and patient information, including important warnings and precautions, potential adverse reactions and drug interactions, please refer to the Package Insert, available here. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. MEDIA CONTACT: Liz Power [email protected] +1 860 501 3849 1 Compared with 2021 average reimbursement rate for all strengths of Dimethyl Fumarate. See Specialty Generic Drugs: A Growing Profit Center for Vertically Integrated Pharmacy Benefit Managers, Federal Trade Commission Second Interim Staff Report, January 2025, at Fig. A2, Table A (pg. 34), available at SOURCE CivicaScript WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED